Proportion of persons (%) with drug treatment, 2007–2020
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |
| N | 257 | 632 | 840 | 1033 | 1130 | 1186 | 1285 | 1351 | 1406 | 1463 | 1553 | 1548 | 1541 | 1484 |
| Glucocorticoids | 84 | 79 | 79 | 77 | 79 | 76 | 80 | 78 | 77 | 76 | 76 | 74 | 71 | 68 |
| DDDs of persons with a glucocorticoid prescription, mean (SD) | 282 (244) | 254 (197) | 233 (167) | 237 (191) | 226 (182) | 211 (159) | 210 (153) | 220 (170) | 217 (166) | 211 (155) | 203 (148) | 204 (156) | 200 (155) | 196 (150) |
| Any csDMARD | 83 | 79 | 77 | 76 | 73 | 70 | 70 | 68 | 67 | 66 | 63 | 59 | 59 | 55 |
| Methotrexate | 39 | 46 | 45 | 44 | 43 | 40 | 40 | 40 | 38 | 37 | 36 | 35 | 35 | 33 |
| Leflunomide | 22 | 23 | 21 | 18 | 18 | 18 | 16 | 16 | 15 | 15 | 14 | 13 | 12 | 10 |
| HCQ | 12 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 11 | 10 | 8.6 | 8.2 |
| Mycophenolate | 3.5 | 1.6 | 1.7 | 1.0 | 0.8 | 0.6 | 0.8 | 0.9 | 1.0 | 1.0 | 0.6 | 1.0 | 1.4 | 2.1 |
| Sulfasalazine | 0.8 | 1.3 | 0.8 | 0.8 | 0.6 | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 | 0.1 | 0.0 | 0.4 | 0.5 |
| Any bDMARD | 16 | 16 | 17 | 18 | 19 | 19 | 19 | 19 | 20 | 22 | 23 | 23 | 24 | 24 |
| TNF inhibitor | 15 | 14 | 15 | 14 | 15 | 15 | 13 | 12 | 13 | 13 | 13 | 12 | 11 | 11 |
| Abatacept | 0.3 | 0.8 | 1.1 | 0.8 | 1.2 | 2.3 | 2.1 | 1.9 | 3.0 | 3.9 | 4.5 | 5.5 | 5.5 | |
| Rituximab | 1.2 | 1.3 | 1.5 | 2.2 | 2.1 | 2.4 | 3.0 | 2.5 | 2.6 | 3.4 | 2.9 | 3.2 | 2.3 | 2.7 |
| Tocilizumab | 0.6 | 1.3 | 2.0 | 2.6 | 2.3 | 3.5 | 3.7 | 3.7 | 3.4 | 3.6 | 4.2 | 3.8 | ||
| JAK inhibitor | 2.1 | 4.0 | 5.6 | 6.5 | ||||||||||
| csDMARD+bDMARD | 11 | 10 | 10 | 12 | 12 | 11 | 10 | 10 | 11 | 11 | 11 | 10 | 11 | 11 |
| NSAIDs | 62 | 61 | 59 | 58 | 57 | 56 | 55 | 52 | 51 | 49 | 46 | 44 | 43 | 38 |
| Analgesics | 35 | 29 | 32 | 31 | 31 | 31 | 36 | 34 | 39 | 40 | 42 | 44 | 43 | 44 |
| Opioids | 35 | 30 | 29 | 29 | 29 | 30 | 31 | 28 | 28 | 30 | 32 | 31 | 30 | 30 |
| Nintedanib | 0.1 | 0.3 | 0.2 | 0.5 | 0.5 | 2.2 | ||||||||
| Pirfenidone | 0.1 | 0.3 | 0.3 | 0.4 | 0.4 | 0.2 | 0.3 | 0.2 | 0.3 | 0.4 |
cs/bDMARD, conventional synthetic/biological disease-modifying antirheumatic drug; DDDs, defined daily doses; HCQ, hydroxychloroquine; JAK, Janus kinase; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.